Abivax SA American Depositary Shares
$ 120.16
-1.89%
17 Apr - close price
- Market Cap 9,782,766,000 USD
- Current Price $ 120.16
- High / Low $ 125.72 / 119.79
- Stock P/E N/A
- Book Value 6.84
- EPS -5.71
- Next Earning Report 2026-06-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -1.36 %
- 52 Week High 148.83
- 52 Week Low 5.59
About
Abivax SA is a clinical-stage biotechnology company dedicated to developing groundbreaking immunotherapies for chronic inflammatory diseases and viral infections, leveraging its lead candidate ABX464, currently undergoing clinical trials for ulcerative colitis and other indications. The firm employs a unique combination of antibody-mediated therapies and proprietary compounds to address significant unmet medical needs, positioning itself favorably within the healthcare landscape. With a promising pipeline and a skilled scientific team committed to innovation, Abivax represents a compelling investment opportunity for institutional stakeholders looking to capitalize on advancements in the immunotherapy sector.
Analyst Target Price
$155.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-23 | 2025-12-15 | 2025-09-08 | 2025-06-02 | 2025-03-24 | 2024-11-07 | 2024-09-09 | 2024-04-02 | 2024-02-06 | 2023-11-29 | 2023-09-21 |
| Reported EPS | -1.18 | -2.47 | -0.89 | -0.95 | -0.8143 | -0.72 | -1.01 | -0.7903 | 0 | -0.64 | -0.72 |
| Estimated EPS | -1.04 | -0.79 | -0.95 | -0.76 | -1.29 | -0.79 | -0.97 | -0.6 | -0.92 | -0.64 | 0 |
| Surprise | -0.14 | -1.68 | 0.06 | -0.19 | 0.4757 | 0.07 | -0.04 | -0.1903 | 0.92 | 0 | -0.72 |
| Surprise Percentage | -13.4615% | -212.6582% | 6.3158% | -25% | 36.876% | 8.8608% | -4.1237% | -31.7167% | 100% | 0% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-06-01 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.07 |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABVX
2026-04-16 14:39:31
LifeSci Capital analyst Sam Slutsky has reiterated a buy rating for Abivax S.A. (ABVX.US), maintaining a target price of $170. According to TipRanks data, Slutsky has a 51.7% success rate and an average return of 40.2% over the past year. This information is provided for informational purposes only and does not constitute investment advice.
2026-04-15 15:09:46
ABIVAX (ABVX) has appointed Michael Nesrallah as its new Chief Commercial Officer. This strategic hire aims to strengthen the company's commercial leadership as it continues to advance its therapeutic pipeline.
2026-04-11 11:10:49
Tudor Investment Corp initiated a new position in Abivax SA (ABVX), purchasing 32,883 shares valued at approximately $2.79 million in the third quarter. Institutional investors now collectively own about 47.91% of Abivax, a clinical-stage biopharmaceutical company focused on chronic inflammatory diseases. Analysts have a "Moderate Buy" rating on the stock with an average target price of $137.15.
2026-04-06 08:07:05
Harbor Capital Advisors Inc. has initiated a new position in Abivax SA Sponsored ADR (ABVX) during the fourth quarter, acquiring 8,849 shares valued at approximately $1.19 million. Several institutional investors have also adjusted their holdings in Abivax, which currently holds a "Moderate Buy" consensus rating with a mean target price of $137.15 from analysts. Despite the positive analyst sentiment, the company is unprofitable, with a forecasted negative EPS of -2.83 for the current year.
2026-04-04 12:39:46
This article details Bronte Capital Management Pty Ltd.'s historical holdings in Abivax SA (ABVX). As of December 31, 2025, Bronte Capital held no shares but had made one purchase and one sale of ABVX, resulting in an estimated gain of $7.56 million. The piece also includes a list of recent news articles related to Abivax SA.
2026-04-04 07:39:46
Aberdeen Group plc significantly reduced its stake in Abivax SA, selling 45.8% of its holdings in Q4 2025, while other institutional investors like UBS Group AG and Darwin Global Management Ltd. substantially increased their positions. Despite Aberdeen's reduction, institutional ownership remains high at 47.91%. Abivax trades near $118.37 with a "Moderate Buy" consensus rating and an average price target of $137.15.
